Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Journal of the American College of CardiologyOpen Access

Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMilton PackerMZMichael R. ZileCKChristopher M. Kramer

Discussion

Loading...

Member takes

Overview

Double-blind trial assessed tirzepatide's impact on heart failure outcomes in diabetic patients, indicating its potential benefits.

Key Points

  • Tirzepatide significantly reduced cardiovascular death events in patients with heart failure, regardless of diabetes status.
  • Patients with type 2 diabetes lost 10.4% of body weight, while those without diabetes lost 12.9%, indicating diminished weight loss effects.
  • The improvement in health status and functional capacity was comparable between patients with and without diabetes.
  • Despite less weight loss, tirzepatide effectively reduced left ventricular mass and paracardiac fat in both groups.

Cite This Study

Packer et al. (2025) studied this question.

synapsesocial.com/papers/68c239e5b210217d6477db0fhttps://doi.org/10.1016/j.jacc.2025.06.058
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management2026
  2. 21722-P: Effect of Tirzepatide on Cardiac Arrhythmia in Adults with Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis2026
  3. 3Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review2025
  4. 4Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis2025
  5. 5Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol2025